NCT02559492 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02559492
Title	INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Incyte Corporation
Indications	melanoma head and neck squamous cell carcinoma triple-receptor negative breast cancer Advanced Solid Tumor renal pelvis transitional cell carcinoma endometrial cancer renal cell carcinoma urethra transitional cell carcinoma pancreatic ductal adenocarcinoma ureter transitional cell carcinoma colorectal cancer bladder urothelial carcinoma stomach cancer
Therapies	Epacadostat + Itacitinib Itacitinib + Parsaclisib
Age Groups:	adult \| senior
Covered Countries	USA

City	State	Country	Details
Duarte	California	United States	Details
Denver	Colorado	United States	Details
New Haven	Connecticut	United States	Details
Tampa	Florida	United States	Details
Chicago	Illinois	United States	Details
Rochester	Minnesota	United States	Details
Huntersville	North Carolina	United States	Details
Nashville	Tennessee	United States	Details
Dallas	Texas	United States	Details
Houston	Texas	United States	Details
Salt Lake City	Utah	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02559492Clinical Trial Detail